Trial Profile

An Open-label, Non-randomized, Single-dose, Parallel-group, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib Administered at 300 mg in Fasted, Hepatically-impaired Male and Female Subjects and Fasted Matched-control Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tucatinib (Primary)
Indications Biliary cancer; Bladder cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; HER2 positive breast cancer; Non-small cell lung cancer; Solid tumours
Focus Pharmacokinetics
Sponsors Seagen

05 Dec 2022 Results of PK and safety of tucatinib in volunteers with hepatic impairment, published in the Clinical Pharmacokinetics
10 Apr 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research.
16 May 2019 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com